Is There a Need for Immunopharmacologic Guidance of Anti-Tumor Necrosis Factor Therapies?

被引：47

作者：

Bendtzen, Klaus ^{[1
]}

机构：

[1] Copenhagen Univ Hosp, Rigshosp, Inst Inflammat Res, DK-2100 Copenhagen, Denmark

来源：

ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 04期

关键词：

CLINICAL-RESPONSE; THROMBOEMBOLIC EVENTS; RHEUMATOID-ARTHRITIS; ANTIBODIES; IMMUNOGENICITY; INFLIXIMAB; BIOAVAILABILITY; ADALIMUMAB; ARTERIAL;

D O I：

10.1002/art.30207

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

引用

页码：867 / 870

页数：4

共 17 条

[1]

Immunogenicity of anti-tumor necrosis factor antibodies - toward improved methods of anti-antibody measurement [J].

Aarden, Lucien ;

Ruuls, Sigrid R. ;

Wolbink, Gertjan .

CURRENT OPINION IN IMMUNOLOGY, 2008, 20 (04) :431-435

[2]

Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease [J].

Ainsworth, Mark A. ;

Bendtzen, Klaus ;

Brynskov, Jorn .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (04) :944-948

[3]

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis [J].

Bartelds, Geertje M. ;

Wijbrandts, Carla A. ;

Nurmohamed, Michael T. ;

Stapel, Steven ;

Lems, Willem F. ;

Aarden, Lucien ;

Dijkmans, Ben A. C. ;

Tak, Paul Peter ;

Wolbink, Gerrit Jan .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (07) :921-926

[4]

Bendtzen Klaus, 2008, V8, P189

[5]

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab [J].

Bendtzen, Klaus ;

Geborek, Pierre ;

Svenson, Morten ;

Larsson, Lotta ;

Kapetanovic, Meliha C. ;

Saxne, Tore .

ARTHRITIS AND RHEUMATISM, 2006, 54 (12) :3782-3789

[6]

Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies [J].

Bendtzen, Klaus ;

Ainsworth, Mark ;

Steenholdt, Casper ;

Thomsen, Ole Ostergaard ;

Brynskov, Jorn .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2009, 44 (07) :774-781

[7]

Clinical immunotoxicity of therapeutic proteins [J].

Descotes, Jacques ;

Gouraud, Aurore .

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2008, 4 (12) :1537-1549

[8]

Bronchospasm associated with anti-TNF treatment [J].

Dubey, S. ;

Kerrigan, N. ;

Mills, K. ;

Scott, D. G. .

CLINICAL RHEUMATOLOGY, 2009, 28 (08) :989-992

[9]

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial [J].

Klareskog, L ;

van der Heijde, D ;

de Jager, JP ;

Gough, A ;

Kalden, J ;

Malaise, M ;

Mola, EM ;

Pavelka, K ;

Sany, J ;

Settas, L ;

Wajdula, J ;

Pedersen, R ;

Fatenejad, S ;

Sanda, M .

LANCET, 2004, 363 (9410) :675-681

[10]

Venous and Arterial Thromboembolic Events in Adalimumab-Treated Patients With Antiadalimumab Antibodies [J].

Korswagen, L. A. ;

Bartelds, G. M. ;

Krieckaert, C. L. M. ;

Turkstra, F. ;

Nurmohamed, M. T. ;

van Schaardenburg, D. ;

Wijbrandts, C. A. ;

Tak, P. P. ;

Lems, W. F. ;

Dijkmans, B. A. C. ;

van Vugt, R. M. ;

Wolbink, G. J. .

ARTHRITIS AND RHEUMATISM, 2011, 63 (04) :877-883

← 1 2 →